Department of Pharmacology, and Center for Molecular Design, University of Virginia Health System, Charlottesville, VA 22908, USA.
Annu Rev Physiol. 2010;72:247-72. doi: 10.1146/annurev-physiol-021909-135917.
As ligand-regulated transcription factors, the nuclear hormone receptors are nearly ideal drug targets, with internal pockets that bind to hydrophobic, drug-like molecules and well-characterized ligand-induced conformational changes that recruit transcriptional coregulators to promoter elements. Yet, due to the multitude of genes under the control of a single receptor, the major challenge has been the identification of ligands with gene-selective actions, impacting disease outcomes through a narrow subset of target genes and not across their entire gene-regulatory repertoire. Here, we summarize the concepts and work to date underlying the development of steroidal and nonsteroidal receptor ligands, including the use of crystal structures, high-throughput screens, and rational design approaches for finding useful therapeutic molecules. Difficulties in finding selective receptor modulators require a more complete understanding of receptor interdomain communications, posttranslational modifications, and receptor-protein interactions that could be exploited for target gene selectivity.
作为配体调控的转录因子,核激素受体是近乎理想的药物靶点,其内部口袋可与疏水性、类似药物的分子结合,并具有特征明确的配体诱导构象变化,从而募集转录共激活因子到启动子元件。然而,由于单个受体控制的基因数量众多,主要的挑战一直是鉴定具有基因选择性作用的配体,通过少数目标基因而不是整个基因调控谱来影响疾病结果。在这里,我们总结了甾体和非甾体受体配体开发的概念和迄今为止的工作,包括晶体结构、高通量筛选和合理设计方法的使用,以寻找有用的治疗分子。发现选择性受体调节剂的困难需要更全面地了解受体的域间通讯、翻译后修饰和受体-蛋白相互作用,这些可以被利用来实现靶基因的选择性。